SAN FRANCISCO, Calif., June 16, 2014 (GLOBE NEWSWIRE) -- via PRWEB - CollabRx, Inc. (NASDAQ: CLRX) today announced the successful launch of CancerRx™ - an IOS application designed to help oncologists and pathologists navigate the complex landscape of oncology therapeutic options. CancerRx was formally introduced to physicians at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting that took place May 30-June 3, 2014 in Chicago.
Highlights of the ASCO launch include:
"CancerRx was developed to serve as a trusted clinical decision support tool for physicians to quickly and efficiently translate clinical research advances into practical information that can be routinely used to inform cancer treatment planning at the point of care," said Thomas Mika, chairman, president & CEO of CollabRx. "We are incredibly pleased at the overwhelmingly positive reception of CancerRx by the oncology community and we look forward to building on this early success by continuing to develop CancerRx into an indispensible resource for oncologists and pathologists."
The CancerRx app provides expert-vetted treatment options that take into account the genetics of patients' tumors. These options include published clinical treatment guidelines as well as guidance for "beyond standard of care" options based on medical and scientific evidence. Treatment options are developed in close collaboration with CollabRx's expert advisory network, which is composed of over 75 leading physicians, scientists, and researchers from the nation's most prestigious academic and medical institutions. A special feature of CancerRx is a daily oncology newsfeed from MedPage Today, all with real-time over the air updates.
CollabRx, Inc. (NASDAQ: CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.
CollabRx Safe Harbor Statement
This press release includes forward-looking statements about CollabRx's anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and CollabRx's plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx with the Securities and Exchange Commission. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Gavin J. Gordon, MBA, PhD
Vice President of Business Development & Strategic Alliances
This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2014/06/prweb11945528.htm
CollabRx, Inc. Gavin Gordon +1 415-248-5350